<div id="readability-page-1"><p>Annexon (NASDAQ:ANNX - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.07, FiscalAI reports.</p><h2>Annexon Stock Performance</h2><p>NASDAQ ANNX traded down $0.18 during trading on Thursday, reaching $5.52. The company's stock had a trading volume of 2,357,564 shares, compared to its average volume of 2,106,709. The firm has a market cap of $897.06 million, a price-to-earnings ratio of -4.06 and a beta of 1.22. Annexon has a twelve month low of $1.60 and a twelve month high of $7.18. The business's fifty day moving average price is $5.69 and its 200-day moving average price is $5.08. </p><h2>Analysts Set New Price Targets</h2><p>Several equities research analysts recently commented on ANNX shares. Cantor Fitzgerald  reiterated an &#34;overweight&#34; rating on shares of Annexon in a research note on Wednesday, January 14th. Chardan Capital  reiterated a &#34;buy&#34; rating and set a $16.00 price target on shares of Annexon in a research note on Friday, March 20th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Annexon in a research note on Monday, April 20th. Five investment analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat.com, Annexon presently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $17.00.</p><p><b>Get Our Latest Stock Report on Annexon</b></p><h2>Insider Buying and Selling</h2><p>In other Annexon news, EVP Ted Yednock sold 7,857 shares of Annexon stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.11, for a total value of $40,149.27. Following the transaction, the executive vice president directly owned 97,227 shares in the company, valued at approximately $496,829.97. The trade was a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Dean Richard Artis sold 5,290 shares of Annexon stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $5.10, for a total transaction of $26,979.00. Following the completion of the transaction, the executive vice president owned 123,487 shares in the company, valued at approximately $629,783.70. This represents a 4.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 32,513 shares of company stock valued at $165,973 in the last quarter. Corporate insiders own  11.87% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>Institutional investors have recently bought and sold shares of the business. Landscape Capital Management L.L.C. acquired a new position in  Annexon in the fourth quarter valued at $50,000.  CIBC Bancorp USA Inc. acquired a new position in shares of  Annexon during the third quarter worth about $31,000.  Mercer Global Advisors Inc. ADV acquired a new position in shares of  Annexon during the fourth quarter worth about $52,000.  Engineers Gate Manager LP acquired a new position in shares of  Annexon during the second quarter worth about $32,000.  Finally, Cerity Partners LLC acquired a new position in shares of  Annexon during the fourth quarter worth about $74,000. </p><h2>About Annexon</h2> (Get Free Report)<p>Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company's research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.  </p><p>At the core of Annexon's pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.</p><h2>Read More</h2><ul><li>Five stocks we like better than Annexon</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5OWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Annexon Right Now?</h2><p>Before you consider Annexon, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.</p><p>While Annexon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ANNX

LABU

IBBQ

SBIO

<p>Annexon (NASDAQ:ANNX) reported quarterly earnings of ($0.23) EPS, surpassing expectations by $0.07. The stock traded down to $5.52 with a market cap of $897.06 million. Analysts have mixed ratings, with five recommending a Buy and one a Sell. Recent insider sales totaled 32,513 shares. Institutional investors have also shown interest, acquiring new positions. Annexon focuses on complement-targeted therapies for neurodegenerative diseases, with its lead product, ANX005, in Phase 2 trials.</p>

Market Beat

Annexon

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

Annexon (NASDAQ:ANNX) Announces Quarterly Earnings Results, Beats Expectations By $0.07 EPS